|
|
News Breaks | | | | November 12, 2012 | | 12:55 EDT |  | ACHN, ABT, GILD | Achillion drops after competitors report promising HCV data
Achillion (ACHN), which is developing a hepatitis C virus, or HCV, treatment, is retreating after two other companies reported that their HCV treatments had performed well in tests. Gilead (GILD) reported that it did not detect HCV in the RNA of 25 HCV patients four weeks after they were treated with the company's investigational drug. Meanwhile, Abbott (ABT) said that its HCV treatment, SVR12, had produced "high sustained viral response rates" in patients. In a note to investors earlier today, Deutsche Bank analyst Alethia Young wrote that she expects Gilead to obtain 65% of the HCV market, but she predicts that Achillion will garner a 15% share. Moreover, the analyst believes that Achillion's treatment is simpler and better than that of Abbott. She thinks that the decline in Achillion's stock today is overdone, and recommends buying the shares on weakness. Similarly, Wells Fargo analyst Brian Abraham believes that Achillion's data suggests that its treatment could be as good as or better than that of Abbott’s. Achillion is well-positioned to participate in the HCV market, and today's weakness has created an attractive entry point in the stock, he wrote. In early afternoon trading, Achillion slumped $1.06, or 11.76%, to $7.91. | |
|
News For ACHN;ABT;GILD From The Last 14 Days Check below for free stories on ACHN;ABT;GILD the last two weeks. |
|
|
| May 16, 2013 | | 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
 Subscribe for More Information | | | 10:30 EDT |  | ACHN | Achillion management to meet with Maxim
Subscribe for More Information | | | May 15, 2013 | | 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information | | | 06:06 EDT | | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | | | May 13, 2013 | | 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR | | | May 9, 2013 | | 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information | | | May 7, 2013 | | 06:08 EDT |  | ACHN | Achillion reports Q1 EPS (14c), consensus (15c)
Subscribe for More Information | | | May 6, 2013 | | 12:35 EDT | | ABT | Abbott management to meet with Jefferies
Subscribe for More Information | | | 07:34 EDT | | ABT | Conference Forum to host a summit
Subscribe for More Information | | | 07:18 EDT | | ABT | American Congress of Obstetrics and Gynecology to hold annual meeting
Subscribe for More Information | | |
|
|
|
|
|
|
